chemieunternehmen.com

Evotec AG announced today a strategic collaboration with Petra Pharma Corporation (“Petra”). Through the collaboration, Petra will access Evotec’s INDiGO platform to accelerate the development of its lead programme Petra-01, which is being developed for a range of oncological indications, through to the submission of an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration by the close of 2018. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-forms-collaboration-with-petra-pharma-on-indigo-platform-5667

Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2017. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-fiscal-year-2017-results-leading-external-innovation-5665

Evotec AG has launched its accelerated drug development service INDiGO®. With the launch of INDiGO®, Evotec’s expertise and capabilities are uniquely combined under one roof to deliver better drug candidates to patients faster and more efficiently than standard industry approaches.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-launches-indigor-a-unique-integrated-drug-development-solution-for-accelerating-early-drug-candidates-into-the-clinic-5660

Evotec AG will report its financial results for 2017 on Wednesday, 28 March 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2018. The conference call will be held in English. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-to-report-fiscal-year-2017-results-on-28-march-2018-5657

Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-sanofi-in-exclusive-talks-to-create-an-evotec-led-infectious-disease-open-innovation-rd-platform-5646

According to a press release published today by Novo Holdings, a new fund has been launched focused on new approaches to fight against antimicrobial resistance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/novo-holdings-announce-launch-of-repair-and-formation-of-scientific-selection-board-5641

Evotec AG and MaRS Innovation announced today that they have identified the first project to be developed under their LAB150 partnership. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-mars-innovation-announce-first-funded-project-under-lab150-bridge-5639

Evotec AG and APEIRON Biologics AG, a company focused on cancer immunotherapy, announced today that the companies received the first milestone payment from Sanofi under a 3 party alliance signed in August 2015. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-apeiron-achieve-first-milestone-in-immuno-oncology-alliance-with-sanofi-5635

Evotec AG today announced that it has entered into a research collaboration with the Center for Regenerative Therapies TU Dresden („CRTD“) to discover novel small molecule candidates for retinal diseases.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-research-collaboration-with-crtd-to-discover-novel-therapies-for-retinal-diseases-5652